Deals
Glaxo May Consider Spinoffs After Novartis Deal Integration
- CEO says deal creates options for consumer health, vaccines
- Investors have been pushing for spinoffs to boost shares
Andrew Witty, chief executive officer of GlaxoSmithKline.
Photographer: Chris Goodney/BloombergThis article is for subscribers only.
GlaxoSmithKline Plc Chief Executive Officer Andrew Witty is willing to consider suggestions made by investors to break up the company -- although it may not happen for at least a year or two.
A deal with Novartis AG that closed in March created market-leading businesses in consumer health and vaccines. That gives the U.K.’s biggest drugmaker new options once the integration is complete, Witty said in an interview Tuesday at the J.P. Morgan Healthcare Conference in San Francisco.